Ken Griffin I Mab Transaction History
Citadel Advisors LLC
- $559 Billion
- Q4 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in I Mab stock. As of the latest transaction made, Citadel Advisors LLC holds 14,500 shares of IMAB stock, worth $13,920. This represents 0.0% of its overall portfolio holdings.
Number of Shares
14,500
Previous 56,400
74.29%
Holding current value
$13,920
Previous $69,000
82.61%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding IMAB
# of Institutions
34Shares Held
13.8MCall Options Held
56.4KPut Options Held
5.8K-
Hhlr Advisors, Ltd. Grand Cayman, E95.98MShares$5.74 Million0.19% of portfolio
-
Decheng Capital Management Iii (Cayman), LLC4.17MShares$4 Million3.04% of portfolio
-
Morgan Stanley New York, NY3.54MShares$3.4 Million0.0% of portfolio
-
Sg Americas Securities, LLC476KShares$456,8270.0% of portfolio
-
David A. Siegel Two Sigma Advisers, LP | New York, Ny431KShares$413,5680.0% of portfolio
About I-Mab
- Ticker IMAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 83,098,800
- Market Cap $79.8M
- Description
- I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...